Navigation Links
SeraCare Acknowledges Receipt of Unsolicited Proposal from MSMB Capital
Date:6/23/2011

MILFORD, Mass., June 23, 2011 /PRNewswire/ -- SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today acknowledged the receipt of an unsolicited offer from MSMB Capital proposing to purchase all of the outstanding shares of SeraCare for $4.25 per share. It is anticipated that the SeraCare Board of Directors will review the proposal in due course.

(Logo: http://photos.prnewswire.com/prnh/20110324/NE70714LOGO)

About SeraCare Life Sciences, Inc.:

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these assumptions will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, prolonged impairment of sales from changes in our sales organization, potential difficulties hiring sales personnel with the desired qualifications, revenue shortfalls arising from customer transitions to new products, unpredictability in large customer orders, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, reduced margins resulting from a shift in revenue towards services, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.

Contacts:
Gregory A. Gould
Chief Financial Officer
SeraCare Life Sciences, Inc.
508-244-6400

Sarah Cavanaugh
MacDougall Biomedical Communications
781-235-3060


'/>"/>
SOURCE SeraCare Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SeraCare Life Sciences Announces Renewal of National Institutes of Health Contract to Support Research
2. Independent Committee of Caraco Board Retains Independent Advisors for Consideration of Sun Pharma Proposal to Purchase Outstanding Shares and Caraco Acknowledges Filing of Purported Class Action Lawsuits
3. Axis-Shield Acknowledges World Diabetes Day and Provides an Update on its Growing Diabetes Franchise in Emerging Markets
4. Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution
5. InstaCare Announces Receipt of Technology and Patent Value Analysis Penned by Joseph Wolf, Ph.D and William Walling, CFA
6. Mederi Therapeutics Announces Receipt of FDA 510(k) Clearance for the MDRF1 Radiofrequency Generator
7. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
8. Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering
9. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
10. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
11. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Elekta today ... platform will be the focal point of seven scientific ... European Society for Radiotherapy & Oncology, taking place April ... a state-of-the-art radiotherapy system and a high-field MRI scanner ... see the patient,s anatomy in real time. The MR-linac ...
(Date:4/27/2016)... Massachusetts , April 27, 2016 ... that Jeff Poulton , Chief Financial Officer, will present ... Boston, MA on Wednesday, May 04, ... audio webcast will be available on the Presentations and Webcasts ... a replay of the webcast will be available on this ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
Breaking Medicine Technology:
(Date:4/29/2016)... MO (PRWEB) , ... April 29, 2016 , ... International ... Technology Seminar on May 3 and 4 at the Doubletree by Hilton Hotel in ... is dedicated to marketing and applications technologies for protein ingredients. , At the seminar, ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Society for Assisted ... endocrinologists are required to report in vitro fertilization (IVF) delivery rates ... the practice of assisted reproductive technologies in the United States. , This ...
(Date:4/29/2016)... ... April 29, 2016 , ... Orthodontics Limited, ... founders, Dr. Gemmi and Dr. Middleberg, were asked by Invisalign to ... During the seminar, titled “Advancing the Biomechanics of Invisalign Clear Aligners,” Dr. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ProText Layouts is a set of 30 ... . With ProText Layouts, video editors can create an energetic typography video with ... scale of texts. Creating text-based videos have never been easier. , ProText Layouts ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... today the open availability of a new CDISC standard, Clinical Trial Registry ... clinical trials. This innovative standard will make it possible to build applications ...
Breaking Medicine News(10 mins):